Key takeaways
Rybelsus (semaglutide) and Saxenda (liraglutide) are both medications in the glucagon-like peptide-1 (GLP-1) receptor agonist class, but they are used for different purposes. Rybelsus is FDA-approved to treat Type 2 diabetes, while Saxenda is approved for weight management in certain adults and children. Rybelsus is taken orally once a day, whereas Saxenda is injected under the skin once daily. Both medications are only available as brand-name medications. Common side effects for both include nausea, vomiting, and diarrhea. Both medications carry a risk of thyroid cancer and pancreatitis, and they can cause low blood sugar, especially when taken with other diabetes medications. Rybelsus and Saxenda can interact with other medications by affecting their absorption.
